[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353491-105":59,"doc-detail-353491-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comparing-the-molecular-pharmacological-properties-of-existing-beta-blockers-to-determine-the-theoretically-mostideal-anti-cancer-beta-blocker-original-article-open-access","Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most“Ideal” Anti-Cancer β-Blocker - Original Article - Open Access","","Increasing cellular, animal, and epidemiological evidence links β-blockers with reduced cancer growth and metastasis. Propranolol has been most studied, yet the field lacks comparative clinical trials across off-patent β-blockers. This work aims to define a theoretically “ideal” anti-cancer β-blocker with high β2-adrenoceptor affinity, no partial agonism, and long binding duration, using CHO cells and functional transcription assays to evaluate 35 compounds.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comparing-the-molecular-pharmacological-properties-of-existing-beta-blockers-to-determine-the-theoretically-mostideal-anti-cancer-beta-blocker-original-article-open-access/353491/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comparing-the-molecular-pharmacological-properties-of-existing-beta-blockers-to-determine-the-theoretically-mostideal-anti-cancer-beta-blocker-original-article-open-access/353491.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"本研究提出“理想”的抗癌 β-阻断药需要具备哪些分子药理特征？","Question",{"text":112,"@type":113},"需要具备高亲和力、无部分激动作用，并在 β2-肾上腺素受体上具有较长作用/结合持续时间；部分癌种还关注 β1 或 β3-AR。","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"研究如何评估不同 β-阻断药的亲和力、结合持续时间与内在效能？",{"text":117,"@type":113},"在稳定表达野生型及多态变体的人 β1/β1-肾上腺素受体的 CHO 细胞中，使用 3H-CGP12177 whole-cell binding 测定结合亲和力与持续时间，并通过 CRE-gene 转录评估内在效能与部分激动特征。",{"name":119,"@type":110,"acceptedAnswer":120},"综合三个因素后，研究认为哪些药物可能比普萘洛尔更“理想”？",{"text":121,"@type":113},"在考虑亲和力、结合持续时间与部分激动等因素后，研究指出 carazolol 与 ICI118551 可能比 propranolol 更“理想”，而 carvedilol 由于同时具备更高亲和力、显著更长的 β2（及 β1）结合持续时间且维持较低部分激动，可能更接近理论上的最优选择。","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353491,1790642842,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Pharmacology Research & Perspectives  \nORIGINAL ARTICLE  OPEN ACCESS   \nComparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most“Ideal” Anti-Cancer β-Blocker  \nJillian G. Baker1,2,3  \n1Cell Signalling, COMPARE, School of Life Sciences, C Floor Medical School, Queen's Medical Centre, University of Nottingham, Nottingham,  \nUK | 2Respiratory Medicine, Sherwood Forest Hospitals NHS Trust, King's Mill Hospital, Nottinghamshire, UK | 3Respiratory Medicine, Nottingham  \nUniversity NHS Trust, Queen's Medical Centre, Nottingham, UK Correspondence: Jillian G. Baker ([jillian.baker@nottingham.ac.uk](jillian.baker@nottingham.ac.uk))  \nReceived: 20 October 2025 | Revised: 15 December 2025 | Accepted: 18 December 2025  \nABSTRACT  \nThere is increasing evidence, from cellular, animal and human epidemiological studies, linking β-blockers with reductions in cancer growth and metastasis. Propranolol is the most investigated β-blocker for cancer; although as many different off-patent β-blockers exist, there is little commercial incentive to drive comparative clinical trials. To minimize any chance of endogenous β-agonist driven cancer growth or metastasis, theoretically, the “ideal” anti-cancer β-blocker would have high affinity, no partial agonism, and long duration of action at β2-adrenoceptors (and for some cancers, additionally at β1 or β3-AR) . Using CHO cells stably expressing the wildtype and polymorphic variants of the human β1 and β1-adrenoceptors, this study assessed 35 β-blockers for the affinity and duration of binding (using 3H-CGP12177 whole cell binding) and intrinsic efficacy (CRE-gene transcription). Despite high affinity, some β-blockers had a short binding duration (e.g., alprenolol, bupranolol, levobunolol, nadolol and oxprenolol) . Other compounds had substantial partial agonism (e.g., cyanopindolol, bucindolol, pindolol, pronethaloland xamoterol) and other compounds had a biphasic washout (e.g., bucindolol, timolol, carpindolol, and CGP12177) for reasons unknown. Considering all 3 factors, carazolol and ICI118551 may be more “ideal” than propranolol; however, carvedilol, with higher affinity and substantially longer duration of β2 (and β1) receptor binding than propranolol whilst maintaining low partial agonism, may be the most theoretically optimal. Furthermore, it is already widely used in cardiovascular medicine as an offpatent tablet. Thus, carvedilol may have more optimal molecular pharmacological characteristics for an “anti-cancer” β-blocker than propranolol and could enter prospective comparative clinical trials without needing any further clinical workup.  \n1 | Introduction  \nβ-antagonists (β-blockers), including propranolol, were developed in the 1960s to block endogenous catecholamine activation of cardiovascular β-adrenoceptors (β-AR), reducing cardiac output and improving angina and hypertension [1] .β-antagonists are widely used for heart failure, arrhythmias, ischaemic heart disease, thyrotoxicosis, migraine, anxiety, portal hypertension, cirrhosis and variceal bleeding, hypertension, and glaucoma [2] . In 2008, propranolol, given to  \ntwo children with cardiovascular instability from infantile haemangiomas, was found serendipitously to cause tumor regression [3] . Propranolol rapidly became the first-line treatment for this benign, but sometimes troublesome, vascular tumor [4] . Cancer studies suggest increasing evidence that β-blockers may improve outcomes (including breast, colon, melanoma, ovarian, prostate, liver, esophagus, lung, stomach, head and neck cancers, multiple myeloma, and angiosarcoma) through a variety of catecholamine-driven pathways including modulating metabolism, proliferation, invasion and  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Pharmacology Research","cbCaiudbKlC5kaNq","https://ap.wps.com/l/cbCaiudbKlC5kaNq","pdf",747262,17,"English","# Abstract\n## Introduction\n## Background on β-blockers in cancer","[{\"question\":\"本研究提出“理想”的抗癌 β-阻断药需要具备哪些分子药理特征？\",\"answer\":\"需要具备高亲和力、无部分激动作用，并在 β2-肾上腺素受体上具有较长作用/结合持续时间；部分癌种还关注 β1 或 β3-AR。\"},{\"question\":\"研究如何评估不同 β-阻断药的亲和力、结合持续时间与内在效能？\",\"answer\":\"在稳定表达野生型及多态变体的人 β1/β1-肾上腺素受体的 CHO 细胞中，使用 3H-CGP12177 whole-cell binding 测定结合亲和力与持续时间，并通过 CRE-gene 转录评估内在效能与部分激动特征。\"},{\"question\":\"综合三个因素后，研究认为哪些药物可能比普萘洛尔更“理想”？\",\"answer\":\"在考虑亲和力、结合持续时间与部分激动等因素后，研究指出 carazolol 与 ICI118551 可能比 propranolol 更“理想”，而 carvedilol 由于同时具备更高亲和力、显著更长的 β2（及 β1）结合持续时间且维持较低部分激动，可能更接近理论上的最优选择。\"}]","Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most“Ideal” Anti-Cancer β-Blocker - Original Article - Open Access | PDF",1790105745,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb1263aac548e0989de1df062d7d6a7f.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1edfbaca2b283cbfdb909652560f2c7.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4efdb53aad5ff809692d45b971043934.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d92f82657dce1c3175f797a843e42101.webp",980,1287]